Marvel Biosciences Corp. News Releases

Marvel Biosciences fait le point sur un placement privé pouvant atteindre 3 millions de dollars

Thu, 17 Sep 2026 17:05:00 -0400

Calgary, Alberta--(Newsfile Corp. - 17 septembre 2026) - Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) (« Marvel » ou la « Société ») a annoncé aujourd'hui que, à la suite de ses communiqués de presse des 16 juillet 2026, 19 août 2026 et 9 septembre 2026, elle entend réaliser un placement privé sans courtier (le « Placement ») d'unités de la Société (les « Unités ») au prix de 0,15 $ par Unité. Le Placement portera sur un minimum de 10 000 000 d'Unités, pour un produit brut de 1 500 000 $, et un...

Marvel Biosciences Provides Update on Private Placement for up to $3.0 Million

Thu, 17 Sep 2026 17:05:00 -0400

Calgary, Alberta--(Newsfile Corp. - September 17, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) ("Marvel" or the "Company") announced today that, further to its July 16, 2026, August 19, 2026 and September 9, 2026 press releases, it intends to complete a non‐brokered private placement offering (the "Offering") of units of the Company ("Units") at a price of $0.15 per Unit. The Offering will be for a minimum of 10,000,000 Units for gross proceeds of $1,500,000, and up to a maximum...

Marvel Biosciences annonce la prolongation de la date limite de clôture du placement privé

Wed, 09 Sep 2026 14:37:00 -0400

Calgary, Alberta--(Newsfile Corp. - 9 septembre 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) (« Marvel » ou la « Société ») annonce avoir obtenu l'approbation de la Bourse de croissance TSX (« TSXV ») afin de prolonger la date limite de clôture de son placement privé annoncé précédemment (voir les communiqués de presse des 16 juillet 2026 et 19 août 2026) (le « Placement »). La date limite à laquelle la Société doit déposer auprès de la TSXV les documents définitifs relatifs à la...

Marvel Biosciences Announces Extension to Closing Date of Private Placement

Wed, 09 Sep 2026 14:32:00 -0400

Calgary, Alberta--(Newsfile Corp. - September 9, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) ("Marvel" or the "Company") announces that it has received approval from the TSX Venture Exchange ("TSXV") to extend the closing deadline of its previously announced private placement (see July 16, 2026 and August 19, 2026 press releases) (the "Offering"). The deadline by which the Company must file its final closing materials with the TSXV has been extended from August 31, 2026 to...

Marvel Biosciences Announces Grant of Deferred Share Units

Tue, 01 Sep 2026 17:01:00 -0400

Calgary, Alberta--(Newsfile Corp. - September 1, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), announces the award of 50,001 deferred share units ("DSUs") to Marvel's three independent directors, in lieu of cash payment for directors' fees.The DSUs will all vest on September 1, 2027. Vested DSUs shall be settled upon the directors' separation from service from the Company and expire 365 days...

Marvel Biosciences Expands Private Placement to Quebec

Wed, 19 Aug 2026 13:06:00 -0400

Calgary, Alberta--(Newsfile Corp. - August 19, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) ("Marvel" or the "Company") announces that it is expanding its previously announced private placement (see July 16, 2026 press release) to investors resident in the Province of Quebec. There is an amended and restated offering document related to this Offering dated August 19, 2026 that can be accessed under the Company's profile at www.sedarplus.ca and on the Company's website at https://...

Marvel Biosciences Announces Private Placement for up to $3.0 Million

Thu, 16 Jul 2026 16:00:00 -0400

Calgary, Alberta--(Newsfile Corp. - July 16, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) ("Marvel" or the "Company") is pleased to announce that it intends to complete a non‐brokered private placement offering (the "Offering") of units of the Company ("Units") at a price of $0.15 per Unit. The Offering will be for a minimum of 10,000,000 Units for gross proceeds of $1,500,000, and up a maximum of 20,000,000 Units, for gross proceeds of up to $3,000,000.Each Unit will consist of...

Marvel Biosciences Announces Grant of Deferred Share Units

Wed, 20 May 2026 07:00:00 -0400

Calgary, Alberta--(Newsfile Corp. - May 20, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), announces the award of 50,001 deferred share units ("DSUs") to Marvel's three independent directors, in lieu of cash payment for directors' fees.The DSUs will all vest on May 19, 2027. Vested DSUs shall be settled upon the directors' separation from service from the Company and expire 365 days after such...

Marvel Biosciences Announces Closing of Convertible Debenture Offering

Fri, 17 Apr 2026 16:30:00 -0400

Calgary, Alberta--(Newsfile Corp. - April 17, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) ("Marvel" or the "Company") announced today that it has completed the closing of the previously announced non-brokered private placement of unsecured convertible debentures ("Debentures") for gross proceeds of $500,000 (the "Offering"), subject to final approval of the TSX Venture Exchange.The Debentures bear interest at the rate of twelve percent (12%) per annum, payable annually and mature on December...

Marvel Biosciences Announces an Amendment to the Conversion Price for Marvel's Proposed Convertible Debenture Offering

Mon, 13 Apr 2026 17:31:00 -0400

Calgary, Alberta--(Newsfile Corp. - April 13, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) ("Marvel" or the "Company") Further to the Company's press release of April 8, 2026, announcing its intention to complete a non-brokered private placement offering of unsecured convertible debentures ("Debentures") in the principal amount of up to $500,000 (the "Offering"), Marvel wishes to announce that it has amended the conversation price for the Debentures, which are convertible at the holder's option...